Glaxosmithkline Biologicals Sa

Janssen Pharmaceuticals, Inc.

Glycovaxyn Ag

Micha Andres Häuptle

Michael T Kowarik

Michael L Wetter

Stefan Jochen Kemmler

Manuela Mally

Veronica Gambillara

Darren Robert Abbanat

Patricia Ibarra Yon

Veronica Gambillara Fonck

Peter Wilhelmus Maria Hermans

Bert Jacquemyn

Jan Theunis Poolman

Jan Poolman

Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic(ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates ofpolysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of(EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.

Methods and compositions for immune protection against extra-intestinal pathogenic

Provided herein is anO polysaccharide, O25B. Also provided herein are prokaryotic host cells containing enzymes (e.g., glycosyltransferases) used in O25B production. The host cells provided herein produce O25B bioconjugates, wherein said bioconjugates contain O25B linked to a carrier protein. Further provided herein are compositions, e.g., pharmaceutical compositions, including O25B and/or bioconjugates containing O25B. Such compositions can be used as vaccines against infection with ExPEC, and may further include one or more additional bioconjugates.

Polysaccharide and uses thereof

Provided herein is a novelO polysaccharide, O25B. Also provided herein are prokaryotic host cells containing enzymes (e.g., glycosyltransferases) used in O25B production. The host cells provided herein produce O25B bioconjugates, wherein said bioconjugates contain O25B linked to a carrier protein. Further provided herein are compositions, e.g., pharmaceutical compositions, including O25B and/or bioconjugates containing O25B. Such compositions can be used as vaccines against infection with ExPEC, and may further include one or more additional bioconjugates.

Provided herein is a novelO polysaccharide, O25B. Also provided herein are prokaryotic host cells comprising enzymes (e.g., glycosyltransferases) used in O25B production. The host cells provided herein produce O25B bioconjugates, wherein said bioconjugates comprise O25B linked to a carrier protein. Further provided herein are compositions, e.g., pharmaceutical compositions, comprising O25B and/or bioconjugates comprising O25B. Such compositions can be used as vaccines against infection with ExPEC, and may further comprise one or more additional bioconjugates.

Growing community of inventors

Zurich, Switzerland

Micha Andres Häuptle